Literature DB >> 9755125

Characterization of angiotensin IV-degrading enzymes and receptors on rat mesangial cells.

D Chansel1, S Czekalski, S Vandermeersch, E Ruffet, M C Fournié-Zaluski, R Ardaillou.   

Abstract

Because mesangial cells (MC) are a target and a degradation site for angiotensin II (ANG II), we characterized the degrading enzymes and receptors of ANG IV, a metabolite of ANG II, on these cells. ANG IV was metabolized into its NH2-terminal deleted peptides, ANG II-(4-8), ANG II-(5-8), and ANG II-(6-8) by rat MC. Total protection of ANG IV was obtained only when PC-18, a specific aminopeptidase N (APN) inhibitor, and JFH-27A, a mixed inhibitor of dipeptidylaminopeptidase (DAP) and neutral endopeptidase (NEP), were simultaneously added. In contrast, thiorphan, an NEP inhibitor, was inactive. These results demonstrate the exclusive role of APN and DAP in ANG IV degradation. 125I-labeled ANG IV binding was studied in the presence of PC-18 and JFH-27A to suppress ligand degradation. Under these conditions, ANG IV-specific receptors could be demonstrated with a KD of 1.8 nM and a density of 55 fmol/mg. In contrast with MC, no evidence for ANG IV receptors could be obtained in freshly isolated glomeruli. ANG IV stimulated cytosolic calcium concentration in MC, whereas its NH2-terminal deleted metabolites were inactive. Therefore, ANG IV must be protected from degradation by APN and DAP in studies on the nonimmediate biological effects of this peptide.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755125     DOI: 10.1152/ajprenal.1998.275.4.F535

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  Aminopeptidase A inhibitors as potential central antihypertensive agents.

Authors:  A Reaux; M C Fournie-Zaluski; C David; S Zini; B P Roques; P Corvol; C Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

2.  Angiotensin IV upregulates the activity of protein phosphatase 1α in Neura-2A cells.

Authors:  Dan Wang; Peng Xue; Xiu Lan Chen; Zhen Sheng Xie; Fu Quan Yang; Li Zheng; Tao Xu
Journal:  Protein Cell       Date:  2013-06-06       Impact factor: 14.870

3.  AT1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats.

Authors:  Xiao C Li; Duncan J Campbell; Mitsuru Ohishi; Shao Yuan; Jia L Zhuo
Journal:  Am J Physiol Renal Physiol       Date:  2005-12-27

4.  Endothelial metabolism of angiotensin II to angiotensin III, not angiotensin (1-7), augments the vasorelaxation response in adrenal cortical arteries.

Authors:  Phillip G Kopf; William B Campbell
Journal:  Endocrinology       Date:  2013-10-03       Impact factor: 4.736

Review 5.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

Review 6.  Hypertension, RAS, and gender: what is the role of aminopeptidases?

Authors:  María Jesús Ramírez-Expósito; José Manuel Martínez-Martos
Journal:  Heart Fail Rev       Date:  2008-01-24       Impact factor: 4.214

Review 7.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Impaired angiogenesis in aminopeptidase N-null mice.

Authors:  Roberto Rangel; Yan Sun; Liliana Guzman-Rojas; Michael G Ozawa; Jessica Sun; Ricardo J Giordano; Carolyn S Van Pelt; Peggy T Tinkey; Richard R Behringer; Richard L Sidman; Wadih Arap; Renata Pasqualini
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-07       Impact factor: 11.205

Review 9.  New frontiers in the intrarenal Renin-Angiotensin system: a critical review of classical and new paradigms.

Authors:  Jia L Zhuo; Fernanda M Ferrao; Yun Zheng; Xiao C Li
Journal:  Front Endocrinol (Lausanne)       Date:  2013-11-11       Impact factor: 5.555

Review 10.  Aminopeptidase N in arterial hypertension.

Authors:  Robert S Danziger
Journal:  Heart Fail Rev       Date:  2007-11-16       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.